Russian Heart Failure Journal 2009year The use of ACEI in patients with CHF of ischemic genesis


To access this material please log in or register

Register Authorize
2009/

The use of ACEI in patients with CHF of ischemic genesis

Drapkina O. M., Dikur O. N.

Keywords:

DOI:

ACE inhibitors have long proven effective antihypertensive drugs. In recent decade, indications to using these drugs in patients with cardiovascular diseases, primarily CHF, have been tended to expansion. IHD with its most dramatic part, MI, has the biggest share in CHF genesis. Efficacy of ACEI in the treatment of IHD has been demonstrated in many international randomized studies. Potential beneficial effects of ACEI in IHD include restriction of LV and vascular wall media hypertrophy, improvement of endothelial function with resulting slowing of atherosclerosis progression, stabilization of atherosclerotic plaques and reduced risk for thrombosis. Review attempts to analyze possibilities of using ACEI in patients with IHD. Based on available data ramipril and perindopril are drugs of choice for multimodality therapy in patients with IHD
  1. Braunwald E, Domanski MJ, Fowler SE et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004; 351 (20):2058–2068.
  2. Smith SC Jr, Allen J, Blair SN et al. AHA / ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113 (19):2363–2372.
  3. Toda N, Ayajiki K, Okamura T. Interaction of endothelial nitric oxide and angiotensin in the circulation. Pharmacol Rev. 2007; 59 (1):54–87.
  4. Wolf G. «The road not taken»: role of angiotensin II type 2 receptor in pathophysiology. Nephrol Dial Transplant. 2002; 17 (2):195‑198.
  5. Kurisu S, Ozono R, Oshima T et al. Cardiac angiotensin II type 2 receptor activates the kinin / NO system and inhibits fibrosis. Hypertension. 2003; 41 (1):99‑107.
  6. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 2002; 8 (11):1257–1262.
  7. Fox KM, Henderson JR, Bertrand ME et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003; 362 (9386):782‑788.
  8. Køber L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995; 333 (25):1670–1676.
  9. Loke KE, Laycock SK, Mital S et al. Nitric oxide modulates mitochondrial respiration in failing human heart. Circulation. 1999; 100 (12):1291–1297.
  10. Mancini GBJ, Henry GC, Macaya C et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) study. Circulation. 1996; 94 (3):258‑265.
  11. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358 (9287):1033–1041.
  12. Cleland JGF, Erhardt L, Murray G et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE study investigators. Eur Heart J. 1997; 18 (1):41–51.
  13. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after myocardial infarction: AIRE Extension (AIREX) study. Lancet. 1997; 349 (9064):1493–1497.
  14. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000; 342 (3):145‑153.
  15. Lonn E, Yusuf S, Dzavik V et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 2001; 103 (7):919‑925.
  16. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol. 2002; 89 (2A):18A-25A.
  17. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999; 100 (10):1056–1064.
  18. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345 (23):1667–1675.
  19. Teo K, Yusuf S, Sleight P et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial / Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET / TRANSCEND) trials. Am Heart J. 2004; 148 (1):52–61.
  20. Mann JF, Schmieder RE, McQueen M et al Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008; 372 (9638):511‑512.

To access this material please log in or register

Register Authorize
Ru En